Ganoderma lucidum for Managing and Treating Dementia
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Dementia is a form of neurodegenerative disease with a high frequency, mental anomalies, memory loss, and cognitive impairment. Ganoderma lucidum, also called mushroom, possesses biologically active substances that have been shown to possess anti-inflammatory, anti-tumor, anti-aging, immunomodulatory, and antioxidant properties. According to recent research, G. lucidum and its constituents possess capacity against Alzheimer's disease (AD) from several angles, including the ability to improve quality of life, slow the disease's progression, and enhance cognitive performance. Inhibiting tau hyperphosphorylation, preventing Aβ production, influencing activated microglia, controlling the nuclear factor-kappa B (NF-κB)/mitogen-activated protein kinase (MAPK) signaling pathway, preventing neuronal death, modulating the immune system, and inhibiting acetylcholinesterase are the primary underlying mechanisms. The efficacy/potency of G. lucidum and its active ingredients for the management of AD was examined in this chapter, along with important aspects of mechanism research, clinical trials, and additional viewpoints. Because G. lucidum is a natural medicinal fungus effective against several pathophysiologies of AD, it has the potential to be developed as an adjuvant for AD treatment. Clinical studies and further mechanical research may be able to fully realize G. lucidum 's promise as an AD treatment.
Fields of Study & Subjects
Fungal Biology and Applications
Alzheimer's disease research and treatments
Medicinal Plants and Neuroprotection
Publication details
- Journal / source
- CRC Press eBooks
- Pages
- 130–136
- Publication date
- 31 March 2026
- Language
- EN
- Document type
- Book chapter